Journals / Türk Biyokimya Dergisi / 2007 / Cilt: 32 - Sayı: 4

Osteoprotegerin, rank and rank ligand

Osteoprotegerin, rank ve rank ligand

Pages
178–184
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Key Words: Osteoprotegerin, receptor activator of nuclear factor-kappa B, receptor activator of nuclear factor-kappa B ligand, Bone resorption, Immune system,

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The discovery of the osteoprotegerin, receptor activator of nuclear factor-kappa B ligand and receptor activator of nuclear factor-kappa B and identification of their role in osteoclastogenesis provided a major advance in bone biology. receptor activator of nuclear factor-kappa B ligand binds to its receptors on the surface of preosteoclasts and stimulates their differentiation into active osteoclasts, leading to bone resorption.
📊
Key Findings & Data:Osteoprotegerin is a soluble decoy receptor for the receptor activator of nuclear factor-kappa B ligand thereby inhibiting bone resorption.
💡
Conclusion & Impact:Key Words: Osteoprotegerin, receptor activator of nuclear factor-kappa B, receptor activator of nuclear factor-kappa B ligand, Bone resorption, Immune system,
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The discovery of the osteoprotegerin, receptor activator of nuclear factor-kappa B ligand and receptor activator of nuclear factor-kappa B and identification of their role in osteoclastogenesis provided a major advance in bone biology. receptor activator of nuclear factor-kappa B ligand binds to its receptors on the surface of preosteoclasts and stimulates their differentiation into active osteoclasts, leading to bone resorption. Osteoprotegerin is a soluble decoy receptor for the receptor activator of nuclear factor-kappa B ligand thereby inhibiting bone resorption. In addition to providing fundamental insights in bone biology, they may be involved in the immune system, arterial calcification and a number of metabolic bone diseases. In this review, we summarize the roles of receptor activator of nuclear factor-kappa B, receptor activator of nuclear factor-kappa B ligand and osteoprotegerin in bone metabolism, immune system and arterial calcification and discuss their potential in the treatment of these diseases. Key Words: Osteoprotegerin, receptor activator of nuclear factor-kappa B, receptor activator of nuclear factor-kappa B ligand, Bone resorption, Immune system,

Özet

Osteoprotegerin, reseptör aktivatör nükleer kappa B ve reseptör aktivatör nükleer kappa B ligand’ın keşfi ve osteoklastojenezisteki rollerinin belirlenmesi kemik biyolojisinin anlaşılmasına çok önemli katkılar sağlamıştır. Reseptör aktivatör nükleer kappa B ligand preosteoklastların üzerindeki reseptörü reseptör aktivatör nükleer kappa B’e bağlanarak, onların osteoklastlara dönüşmesini uyarır ve böylece kemik rezorpsiyonu oluşur. Osteoprotegerin ise reseptör aktivatör nükleer kappa B ligand için yalancı reseptör görevi görür ve kemik rezorpsiyonunu inhibe eder. Kemik biyolojisinin anlaşılmasına sağladıkları bu temel bakış açısı dışında osteoprotegerin, reseptör aktivatör nükleer kappa B ve reseptör aktivatör nükleer kappa B ligand’ın immün sistem, arteryel kalsifikasyon ve pek çok metabolik kemik hastalığı ile de ilgili olabilecekleri belirtilmiştir. Bu derlemede osteoprotegerin, reseptör aktivatör nükleer kappa B ve reseptör aktivatör nükleer kappa B ligand’ın kemik rezorpsiyonu, immün sistem ve arteryel kalsifikasyondaki rolünün ve tedavideki yerinin özetlenmesi amaçlanmıştır.

🔖

Cite This Article

KURBAN, S., MEHMETOĞLU, İ. (2022). Osteoprotegerin, rank and rank ligand. Türk Biyokimya Dergisi, Cilt: 32 - Sayı: 4, 178–184. https://ajindex.com/articles/621389

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Kostenuik PJ, Shalhoub V. (2001) Osteoprotegerin: A Physiological and Pharmacological Inhibitor of Bone Resorption. Curr Pharm Des. 7: 613-35
  2. Boyce BF, Xing L. (2007) Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 9:1
  3. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davey E, Bucay N, Renshaw- Gregg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ. (1997) Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309–319
  4. Tsuda E, Goto M, Mochizuki SI, Yano K, Kobayashi F, Morinaga T, Higashio K. (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 234: 137–42
  5. Lacey DL, Timms E, Tan H-L, Kelly MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy F, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalboub V, Senaldi G, Guo J, Delaney J, Boyle WJ. (1998) Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93: 165–176
  6. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95: 3597–602
  7. Hofbauer LC. (1999) Osteoprotegerin ligand and osteoprotegerin: Novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol 141: 195–210
  8. Blair JM, Zheng Y, Dunstan CR. (2007) RANK ligand. Int J Biochem Cell Biol. 39: 1077-81
  9. Khosla S. (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology. 142: 5050-5
  10. Schoppet M, Preissner KT, Hofbauer LC. (2002) RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 22: 549-53
  11. Stejskal D, Bartek J, Pastorkova R, Ruzicka V, Oral I, Horalik D. (2001) Osteoprotegerin, RANK, RANKL. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 145: 61-4
  12. Hofbauer LC, Neubauer A, Heufelder AE. (2001) Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone d